WallStreetZenWallStreetZen

NYSE: HLN
Haleon PLC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their HLN stock forecasts and price targets.

Forecast return on equity

Is HLN forecast to generate an efficient return?

Company
11.04%
Industry
284.62%
Market
228.66%
HLN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is HLN forecast to generate an efficient return on assets?

Company
5.2%
Industry
156.25%
HLN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

HLN earnings per share forecast

What is HLN's earnings per share in the next 3 years based on estimates from 20 analysts?

Avg 1 year Forecast
$0.19-52.1%
Avg 2 year Forecast
$0.21-47.14%
Avg 3 year Forecast
$0.23-41.85%
HLN's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

HLN revenue forecast

What is HLN's revenue in the next 3 years based on estimates from 19 analysts?

Avg 1 year Forecast
$11.4B-18.79%
Avg 2 year Forecast
$11.9B-14.99%
Avg 3 year Forecast
$12.5B-11.16%
HLN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

HLN earnings growth forecast

How is HLN forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
-17.59%
Industry
365.91%
Market
42.76%
HLN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
HLN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
HLN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

HLN revenue growth forecast

How is HLN forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
-5.09%
Industry
132.44%
Market
25.31%
HLN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
HLN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

HLN vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
HLN$9.82N/AN/A
TAK$14.47N/AN/A
ZTS$122.25$166.89+36.51%Buy
TEVA$30.06$32.33+7.56%Strong Buy
NBIX$141.70$180.50+27.38%Strong Buy
View Top Pharmaceutical Stocks

Haleon Stock Forecast FAQ

What is HLN's earnings growth forecast for 2025-2027?

(NYSE: HLN) Haleon's forecast annual earnings growth rate of -17.59% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 365.91%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.76%.

Haleon's earnings in 2025 is $1,872,727,272.On average, 20 Wall Street analysts forecast HLN's earnings for 2025 to be $1,718,640,944, with the lowest HLN earnings forecast at $1,602,369,252, and the highest HLN earnings forecast at $1,784,043,770. On average, 19 Wall Street analysts forecast HLN's earnings for 2026 to be $1,896,681,972, with the lowest HLN earnings forecast at $1,735,900,023, and the highest HLN earnings forecast at $2,010,228,546.

In 2027, HLN is forecast to generate $2,086,531,844 in earnings, with the lowest earnings forecast at $1,869,430,794 and the highest earnings forecast at $2,272,748,225.

If you're new to stock investing, here's how to buy Haleon stock.

What is HLN's revenue growth forecast for 2025-2027?

(NYSE: HLN) Haleon's forecast annual revenue growth rate of -5.09% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 132.44%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.31%.

Haleon's revenue in 2025 is $14,588,311,688.On average, 19 Wall Street analysts forecast HLN's revenue for 2025 to be $103,581,726,654,357, with the lowest HLN revenue forecast at $97,441,127,933,113, and the highest HLN revenue forecast at $107,088,044,859,091. On average, 19 Wall Street analysts forecast HLN's revenue for 2026 to be $108,423,352,569,184, with the lowest HLN revenue forecast at $100,375,171,404,950, and the highest HLN revenue forecast at $114,445,862,853,481.

In 2027, HLN is forecast to generate $113,310,397,113,606 in revenue, with the lowest revenue forecast at $105,425,723,015,914 and the highest revenue forecast at $120,141,359,004,694.

What is HLN's forecast return on assets (ROA) for 2025-2028?

(NYSE: HLN) forecast ROA is 5.2%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 156.25%.

What is HLN's Earnings Per Share (EPS) forecast for 2025-2027?

(NYSE: HLN) Haleon's current Earnings Per Share (EPS) is $0.41. On average, analysts forecast that HLN's EPS will be $0.19 for 2025, with the lowest EPS forecast at $0.18, and the highest EPS forecast at $0.20. On average, analysts forecast that HLN's EPS will be $0.21 for 2026, with the lowest EPS forecast at $0.19, and the highest EPS forecast at $0.22. In 2027, HLN's EPS is forecast to hit $0.23 (min: $0.21, max: $0.25).

What is HLN's forecast return on equity (ROE) for 2025-2028?

(NYSE: HLN) forecast ROE is 11.04%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.